Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6331635 | SANOFI AVENTIS US | Taxoids, their preparation and pharmaceutical compositions containing them |
Mar, 2016
(8 years ago) | |
US5847170 | SANOFI AVENTIS US | Taxoids, their preparation and pharmaceutical compositions containing them |
Mar, 2021
(3 years ago) | |
US7241907 | SANOFI AVENTIS US | Acetone solvate of dimethoxy docetaxel and its process of preparation |
Dec, 2025
(1 year, 7 months from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5698582 | SANOFI AVENTIS US | Compositions containing taxane derivatives |
Jul, 2012
(11 years ago) | |
US5438072 | SANOFI AVENTIS US | Taxoid-based compositions |
Nov, 2013
(10 years ago) | |
US6372780 | SANOFI AVENTIS US | Methods of treating cell lines expressing multidrug resistance P-glycoprotein |
Mar, 2016
(8 years ago) | |
US6387946 | SANOFI AVENTIS US | Methods for treating pathological conditions of abnormal cell proliferation |
Mar, 2016
(8 years ago) | |
US5847170 (Pediatric) | SANOFI AVENTIS US | Taxoids, their preparation and pharmaceutical compositions containing them |
Sep, 2021
(2 years ago) | |
US7241907 (Pediatric) | SANOFI AVENTIS US | Acetone solvate of dimethoxy docetaxel and its process of preparation |
Jun, 2026
(2 years from now) | |
US10583110 | SANOFI AVENTIS US | Antitumoral use of cabazitaxel |
Oct, 2030
(6 years from now) | |
US8927592 | SANOFI AVENTIS US | Antitumoral use of cabazitaxel |
Oct, 2030
(6 years from now) | |
US10716777 | SANOFI AVENTIS US | Antitumoral use of cabazitaxel |
Oct, 2030
(6 years from now) | |
US8927592 (Pediatric) | SANOFI AVENTIS US | Antitumoral use of cabazitaxel |
Apr, 2031
(7 years from now) |
Jevtana Kit is owned by Sanofi Aventis Us.
Jevtana Kit contains Cabazitaxel.
Jevtana Kit has a total of 13 drug patents out of which 7 drug patents have expired.
Expired drug patents of Jevtana Kit are:
Jevtana Kit was authorised for market use on 17 June, 2010.
Jevtana Kit is available in solution;intravenous dosage forms.
Jevtana Kit can be used as increasing survival in mcrpc patients previously treated with docetaxel by administering cabazitaxel in combination with prednisone or prednisolone after a premedication regimen that includes an antihistamine, a corticosteroid, and an h2-antagonist, increasing survival in metastatic castration-resistant prostate cancer patients previously treated with docetaxel by administering as a 3 week cycle cabazitaxel after 5 mg dexchlorpheniramine, 8 mg dexamethasone, and an h2-agonist, increasing survival in metastatic castration-resistant prostate cancer patients previously treated with docetaxel by administering 20 to 25 mg/m2 cabazitaxel after a premedication regimen that includes an h2-antagonist, treatment of cancer.
Drug patent challenges can be filed against Jevtana Kit from 18 November, 2019.
The generics of Jevtana Kit are possible to be released after 27 April, 2031.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-209) | Sep 14, 2020 |
M(M-201) | May 17, 2020 |
M(M-128) | Dec 18, 2023 |
Pediatric Exclusivity(PED) | Nov 17, 2020 |
New Chemical Entity Exclusivity(NCE) | Jun 17, 2015 |
Drugs and Companies using
CABAZITAXEL ingredient